TASIGNA

novartis pharmaceuticals canada inc🇨🇦 Health Canada

Approval Id: eb03fa73e79c54f9
Drug Approval Canada Name: TASIGNA
Product Name: TASIGNA
Status: Cancelled Post Market
Status Date: 2023-10-04
Original Market Date: 2019-05-17
Din: 02481715
Drug Class: Human
Dosage Form: Capsule
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 10:00.00
Atc Original: L01EA03 NILOTINIB
Atc Name: l 01 ea 03
Aig Number: 0152484003
Company Name: novartis pharmaceuticals canada inc
Company Address: 100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1

NILOTINIB (NILOTINIB HYDROCHLORIDE MONOHYDRATE)

50 MG

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

eb03fa73e79c54f9

Type

Standard